The Library
Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin
Tools
Tools
Tools
Carroll, Tamara Y., Mulla, Melissa J., Han, Christina S., Brosens, Jan J., Chamley, Larry W., Giles, Ian, Pericleous, Charis, Rahman, Anisur, Sfakianaki, Anna K., Paidas, Michael J. and Abrahams, Vikki M. (2011) Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin. American Journal of Reproductive Immunology, Vol.66 (No.4). pp. 286-296. doi:10.1111/j.1600-0897.2011.01007.x ISSN 1046-7408.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1111/j.1600-0897.2011.01007.x
Abstract
Problem Women with antiphospholipid antibodies (aPL) are at risk of miscarriage and pre-eclampsia, obstetrical disorders associated with reduced trophoblast invasion and spiral artery transformation. aPL target the placenta by binding beta2-glycoprotein I (β2GPI) on the trophoblast. In this study, we determined whether aPL alter the trophoblast secretion of angiogenic factors and evaluated the effect of low molecular weight heparin (LMWH) on this response.
Method of study First-trimester trophoblast was treated with anti-β2GPI antibodies with or without LMWH. Angiogenic factor secretion was measured by enzyme-linked immunosorbent assay.
Results Trophoblast cells produced more vascular endothelial growth factor (VEGF), placenta growth factor (PlGF), and soluble endoglin following exposure to anti-β2GPI Abs, and this occurred in both a MyD88-dependent and MyD88-independent manner. LMWH was unable to reverse the effects of the anti-β2GPI Abs on trophoblast VEGF secretion, but enhanced PlGF. Strikingly, LMWH upregulated soluble fms-like tyrosine kinase receptor-1 (sFlt-1) secretion independently of aPL.
Conclusion This study demonstrates that aPL perturb the secretion of trophoblast angiogenic factors. LMWH does not reverse this effect but exacerbates sFlt-1 secretion, a potent anti-angiogenic factor. These findings may help to explain why women with antiphospholipid syndrome, who are treated with heparin to prevent early pregnancy loss, remain at increased risk of developing late obstetrical complications, such as pre-eclampsia.
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > RG Gynecology and obstetrics | ||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Reproductive Health ( - until July 2016) Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
| Journal or Publication Title: | American Journal of Reproductive Immunology | ||||
| Publisher: | Wiley-Blackwell Publishing, Inc. | ||||
| ISSN: | 1046-7408 | ||||
| Official Date: | October 2011 | ||||
| Dates: |
|
||||
| Volume: | Vol.66 | ||||
| Number: | No.4 | ||||
| Page Range: | pp. 286-296 | ||||
| DOI: | 10.1111/j.1600-0897.2011.01007.x | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Restricted or Subscription Access |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
